Automated Synthesis and Initial Evaluation of (4-Amino-5,8-difluoro-1H-spiro[piperidine-4,2-quinazolin]-1-yl)(4-[¹⁸F]fluorophenyl)methanone for PET/MR Imaging of Inducible Nitric Oxide Synthase

Figure 10

Comparative analysis of [¹⁸F]FBAT PET/MRI and immunohistochemical (IHC) staining for iNOS in the cortex and cerebellum. (a) Representative sagittal PET/MR images obtained 30 min postinjection of [¹⁸F]FBAT in control, LPS-induced mice, and LPS-induced mice pretreated with aminoguanidine. [¹⁸F]FBAT accumulation significantly decreased in all brain regions after administration of aminoguanidine. Color coding of the images is set to maximize the visualization of [¹⁸F]FBAT accumulation in each projection. (b) Validation of [¹⁸F]FBAT PET using histopathological analyses of iNOS expression in the brain at 3 h or 24 h postinjection of LPS. Stronger iNOS (+) imaging is representative of the positive staining results obtained in the cortex, cerebellum, and brainstem in the 3 h LPS-induced mice compared to the 24 h LPS-induced group and controls. Pretreatment with aminoguanidine significantly reduced iNOS immunoactivity in the cortex and brainstem, but not in the cerebellum. Scale . Data are ; per group; compared to the control group; ^# and ^## compared to the LPS 3 h group.

(a)

(b)